Protein SLC26A9 Influences Ion and Fluid Secretion in Epithelial Tissue
Recent research suggests that the gene SLC26A9 is a modifier gene for cystic fibrosis, meaning it can influence the severity of the disease. It is also believed to play a role in other lung diseases, but the exact mechanisms remain unknown. What is clear, however, is that the protein encoded by this gene, SLC26A9, functions as a chloride transporter and plays a crucial role in the coordinated secretion of ions and fluids in epithelial tissues affected by CF, including the airways, pancreas, and gastrointestinal tract.
Understanding the molecular mechanisms of SLC26A9 and its interaction with the CFTR channel is a key goal of Stanke and Balázs’ research. This knowledge could potentially open up new therapeutic options aimed at restoring chloride and fluid secretion in CF patients.

Investigating SLC26A9 at the Protein Level Using a Specific Antibody
Genetic studies of single cells have already confirmed that human airway cells express the SLC26A9 gene (meaning they produce the corresponding protein). However, the SLC26A9 protein itself has not yet been detected.
To reliably study SLC26A9 at the protein level, researchers require a high-quality, specific antibody—a critical tool that is currently unavailable. The current project aims to test whether a custom-made antibody developed by the company Eurogentec can reliably detect the SLC26A9 protein. If successful, this antibody will then be used to analyze SLC26A9 protein synthesis in the context of cystic fibrosis.
“We have high hopes that this project will provide us with a new antibody that can be used in future cystic fibrosis research,” says PD Dr. Frauke Stanke, a researcher at BREATH.

Outlook: Unlocking New Therapeutic Approaches
If the project succeeds, the SLC26A9 antibody will be made available to other researchers via Eurogentec. It could then be used to:
•    Identify and preclinically test SLC26A9-modulating drugs
•    Examine possible interactions between CFTR protein maturation (e.g., CFTR modulator therapies) and SLC26A9 protein processing

With years of experience in cystic fibrosis research, PD Dr. Stanke remains optimistic: “Cystic fibrosis research and therapy have advanced tremendously in recent years, and we are already able to help many patients. With this project, we hope to find additional treatment approaches.” Additionally, a specific antibody against SLC26A9 could help researchers better understand the impact of CF-related changes, such as inflammatory processes, on SLC26A9 production in airway epithelial cells.
 

Text: Mukoviszidose e.V.

Photo: private